AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06311201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates exercises
Description: The Pilates exercise program for the study group (B) consisted of a 10-minute warm-up with low-intensity exercises, followed by a 40-minute central part with floor exercises like leg circles, kicks, and stretches. It included the classic hundred exercise, performed with proper form. Each exercise had two sets of 10 repetitions. The session ended with a 10-minute cool-down of stretching exercises, supervised by a physical therapist. The program was conducted three times per week, one hour per session, for eight weeks, starting from the 7th day after delivery.
Study NCT06699576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Adebrelimab: administered as an IV infusion
Study NCT06699420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qishenyiqi dripping pills 1 bag, three times a day
Description: Qishenyiqi dripping pills, 1 bag once, three times a day, 12 months
Study NCT06699420 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1 bag, three times a day
Description: Placebo, 1 bag once, three times a day, 12 months
Study NCT06053684 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Non-Invasive Mechanical Servo Ventilation
Description: The active comparator arm will utilize a standard non-invasive mode to provide ventilation support
Study NCT06053684 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurally-Adjusted Ventilatory Assistance (NAVA) Non-Invasive Mechanical Servo Ventilation
Description: The experimental arm will utilize a NAVA mode to provide non-invasive ventilation support
Study NCT04252547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kangaroo Care
Description: The preprocedural measurements (weight, heart rate, and oxygen saturation) will be recorded before the first feeding hour when they are included in the study and then they will be held on their mothers' chest for skin-to-skin kangaroo care for half an hour. Their heart rate and oxygen saturation will be recorded for half an hour. At the end of the kangaroo care, the infant will be breastfed by his/her mother. A chronometer will be started at that moment he/she begins sucking and terminated when he/she stops. The infant's heart rate and oxygen saturation will also continue to be recorded during the breastfeeding process. When the breastfeeding process is over, the infant will be allowed to rest in his/her mother's arms for two minutes and his/her physiological parameters will be recorded. Following the breastfeeding process, the infant will be weight is measured without a diaper change and his/her weight will be recorded. Then he/she will be taken back in the incubator to sleep.
Study NCT04252547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: The preprocedural measurements (weight, heart rate, and oxygen saturation) will be recorded before feeding when they are included in the study and then they will be breastfed by their mothers. The chronometer will be started at that moment he/she begins sucking and terminated when he/she stops. Also, the infant's heart rate and oxygen saturation will continue to be recorded during the breastfeeding process. When the breastfeeding process is over, the infant will be allowed to rest in his/her mother's arms for two minutes and his/her physiological parameters will be recorded. Following the breastfeeding process, the infant will be weighed without a diaper change and his/her weight will be recorded. When the care process is over, it will be taken back in the incubator to sleep.
Study NCT06801405 — intervention group
Intervention type: DRUG
Intervention: antibiotic prophylaxis
Description: Antibiotic prophylaxis before percutaneous nephrostomy
Study NCT06800105 — intervention group
Intervention type: OTHER
Intervention: High fat smoothie
Description: Participants will consume a standardized 490 kcal high-fat smoothie, consisting of 57% fat, 23% carbohydrate, and 20% protein.
Study NCT06801197 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MI-Coach: ED Mobile App
Description: The MI-Coach: ED mobile app is a self-guided intervention designed to enhance motivation and readiness for treatment in adults with eating disorders. The app includes seven sequential modules based on motivational interviewing (MI) principles, addressing ambivalence, self-acceptance, compassionate motivation, behavior change goals, sustain and change talk, commitment language, and relapse prevention. Each module incorporates interactive content, including educational videos, articles, and exercises, tailored to support motivation across a range of eating disorder diagnoses. The app is designed to be user-friendly and scalable, providing an accessible, cost-effective solution for individuals on waitlists for formal eating disorder treatment.
Study NCT06801353 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stapokibart
Description: Stapokibart subcutaneously every two weeks
Study NCT06801353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate Nasal Spray (MFNS)
Description: mometasone furoate nasal spray 200 μg once daily
Study NCT06801054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)
Description: All patients will receive a second dose of tenecteplase.
Study NCT06800677 — intervention group
Intervention type: PROCEDURE
Intervention: Hysterectomy
Description: Elective hysterectomy
Study NCT06800898 — intervention group
Intervention type: OTHER
Intervention: Blood samples and Questionnaires
Description: Blood samples for methylation of the promoter of the OX-A and OX-B genes and questionnaires:~Eating Disorder Examination Q Eating Disorder Inventory 3 Major Depression Inventory Symptom Checklist-revised ESS - Epworth Sleepiness Scale Pittsburgh Sleep Quality Index Horne \& Ostberg questionnaire
Study NCT05126277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ianalumab s.c. q4w
Description: ianalumab s.c. q4w in addition to SoC
Study NCT05126277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ianalumab s.c. q12w
Description: ianalumab s.c. q12w in addition to SoC
Study NCT05126277 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo s.c.
Description: placebo s.c. q4w in addition to SoC
Study NCT06801483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening
Description: All subjects will recieve an ankle muscle strenghening training program twice a week for six weeks.
Study NCT06801483 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strengthening
Description: All subjects will recieve an ankle muscle strenghening training program twice a week for six weeks.
Study NCT06115135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: All subjects in Dose Level 0 will receive 1) venetoclax, PO, at 400 mg every day (QD) on Days 1-28 of a 28-day cycle, 2) dexamethasone 40 mg IV, once weekly on Days 1, 8, 15, and 22 of a 28-day cycle; and 3) isatuximab 10mg/kg, IV, on Days 1, 8, 15, and 22 of the first 28-day cycle, and then Days 1 and 15 during subsequent 28-day cycles.
Study NCT04610372 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Hypofractionated external beam radiotherapy
Description: 5500 cGy/20 fractions delivered 5 days per week over 4 weeks
Study NCT04610372 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High dose rate brachytherapy
Description: A single fraction of 19 Gy is delivered from an automated afterloading Iridium-192 source via interstitial catheters placed under ultrasound guidance
Study NCT04610372 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Permanent seed implant
Description: Iodine-125 radioactive seeds are implanted permanently in the prostate in a single procedure under transrectal ultrasound guidance
Study NCT04610372 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: External radiation using SABR technology delivers 36.25 Gy to the prostate in 5 fractions given either once weekly for 5 weeks or every second day over 2 weeks.
Study NCT05337371 — intervention group
Intervention type: DEVICE
Intervention: ECG patch (Philips ePatch® 2.0)
Description: The ECG patch will be put on the patients chest to monitor cardiac activity for a total time period of 14 days after cardiac arrest.
Study NCT05551663 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric exercise training
Description: Participants randomised to the intervention will perform a 4-week programme of isometric exercise training.
Study NCT04655430 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3-second SDF application
Description: Dosage: 3-second 38% SDF solution application
Study NCT04655430 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5-second SDF application
Description: Dosage: 5-second 38% SDF solution application
Study NCT04655430 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 10-second SDF application
Description: Dosage: 10-second 38% SDF solution application
Study NCT06698809 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tPBM
Description: tPBM is a neuromodulatory treatment that uses red and/or near infrared light to penetrate the cortex and can alter both cerebral metabolism and blood flow. Subjects will receive treatment for approximately 12 minutes per treatment.
Study NCT06699381 — intervention group
Intervention type: DEVICE
Intervention: use of spinal mouse
Description: Spinal Mouse (SM) is an external non-invasive measurement device that evaluates the spinal angle and shape in the frontal and sagittal planes
Study NCT06699381 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Brunnstrom's Hemiplegia Recovery Staging
Description: According to Brunnstrom's stages of recovery, the individual will be identified at which stage
Study NCT06699381 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The six minute walking test (6MWT)
Description: It evaluates the functional capacity of the individual and it provides valuable information regarding all the systems during physical activity, including pulmonary and cardiovascular systems, blood circulation, neuromuscular units, body metabolism, and peripheral circulation
Study NCT04655430 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 15-second SDF application
Description: Dosage: 15-second 38% SDF solution application
Study NCT06132477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLP-1 receptor agonist
Description: Randomized to continue or discontinue GLP-1 receptor agonists after bariatric surgery
Study NCT05892770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc gluconate supplement
Description: Subjects will take a 50 mg zinc gluconate supplement at breakfast for the five days leading up to their next injection appointment. They will also answer questionnaires and provide audio recordings at various time points of the two injection cycles, which is roughly six months.
Study NCT05892770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: This is the current standard of care for treatment of spasmodic dysphonia. Botox injection goes into the vocal cord muscle, and will be occur in both the control and experimental arms of the study.
Study NCT05892770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: This is the current standard of care for treatment of spasmodic dysphonia. Botox injection goes into the vocal cord muscle, and will be occur in both the control and experimental arms of the study.
Study NCT05799521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optate
Description: Alkaline Buffer
Study NCT05799521 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline
Study NCT05623475 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OSCEs
Description: Scenario-based education intervention, including objective structured clinical examinations (OSCEs)
Study NCT05623475 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lecture
Description: Face-to-face Education using Delirium Care Flip Chart
Study NCT05623475 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lecture
Description: Face-to-face Education using Delirium Care Flip Chart
Study NCT05623475 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: E-learning
Description: Delirium care video
Study NCT05623475 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-learning
Description: Delirium care video
Study NCT05709561 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupresur
Description: acupressure application was applied 2 times a week for a total of 12 weeks and 24 times.
Study NCT06699381 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Functional Reach Test (FRT)
Description: Functional Reach Test (FRT) is a clinical outcome measure and assessment tool for ascertaining dynamic balance in in simple task.~In standing, measures the distance between the length of an outstretched arm in a maximal forward reach, while maintaining a fixed base of support.~This information is correlated with risk of falling A number of factors exert a major influence on this evaluation: Research revealed that movement strategy and reduced spinal flexibility both affect reach distance.
Study NCT06699381 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Mini Balance Evaluation Systems Test (Mini-BESTest)
Description: This test measures dynamic balance, functional mobility, and gait. It is commonly used in populations who have or have had multiple sclerosis (MS), Parkinson disease (PD), strokes, spinal cord injury (SCI), or cancer.~The Mini-BESTest was developed in 2010 from the Balance Evaluation Systems Test (BESTest), then revised in 2013 to clarify inconsistencies in scoring. The scoring instructions were different in the published and online versions. The revision clarified that the Mini-BESTest should be scored out of 28 points. Explanations for how to score items 3, 6, and 14 were also given.~The Mini-BESTest consists of 14 items, including 4 of the 6 sections (anticipatory postural adjustments, reactive postural control, sensory orientation, and dynamic gait) from the BESTest.
Study NCT05709561 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness
Description: Mindfulness practice was applied with the students once a week for 8 weeks, accompanied by a researcher. Then, students were asked to apply for 3 cycles.
Study NCT05709561 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Plasebo
Description: No intervention was applied to the control group.
Study NCT06699381 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The five Times Sit to Stand Test (5x Sit-To-Stand Test)
Description: It's used to asses functional lower limbs strength, transitional movements, balance, and fall risk in older adults.
Study NCT06699381 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The Postural Assessment Scale for Stroke (PASS)
Description: The Postural Assessment Scale for Stroke (PASS) is an outcome measure specifically designed to assess and monitor postural control after stroke. It was developed in 1999 as an adaptation of the Fugl-Meyer Assessment balance subscale\[1\]. It contains 12 four-level items of varying difficulty for assessing ability to maintain or change a given lying, sitting or standing posture
Study NCT06699381 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Postural Symmetry Index and Weight Transfer Symmetry
Description: It is a form of measurement in which two scales are used to calculate the weight transferred to the intact and stroke limb. The values obtained as a result of the test are calculated with formulas.
Study NCT06699381 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of the craniovertebral angle
Description: Measurement of the craniovertebral angle; the patient is asked to find the most natural position by flexion and extension of the head in the standing position and a photograph is taken with a digital camera from a distance of 1.5 m to the shoulder level of the patient and this process is repeated 3 times. The images obtained are then digitally calculated with the help of an appropriate program.
Study NCT04655430 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 30-second SDF application
Description: Dosage: 30-second 38% SDF solution application
Study NCT04655430 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 45-second SDF application
Description: Dosage: 45-second 38% SDF solution application
Study NCT04655430 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 60-second SDF application
Description: Dosage: 60-second 38% SDF solution application
Study NCT04655430 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 120-second SDF application
Description: Dosage: 120-second 38% SDF solution application
Study NCT04655430 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 180-second SDF application
Description: Dosage: 180-second 38% SDF solution application
Study NCT06226012 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulsed magnetic field
Description: Children in this group received pulsed magnetic therapy in addition to traditional exercise program
Study NCT06226012 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low level laser
Description: Children in this group received low level laser therapy in addition to traditional exercise program
Study NCT04697095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: : The blood sample from all groups will be taken on the day of inclusion, in the ophthalmology department. The patient will be cared for by a nurse and then taken to the collection room. A 100 ml sample will be taken (10 tubes of 10 ml). Blood samples will be labeled with the patient's identification number as part of the protocol. They will be transported to the research laboratory in order to be picked up for monocyte extraction. The purification of blood monocytes will be done. In case of excess, the samples will be destroyed at the end of the study.
Study NCT04697095 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Blood samples
Description: : The blood sample from all groups will be taken on the day of inclusion, in the ophthalmology department. The patient will be cared for by a nurse and then taken to the collection room. A 100 ml sample will be taken (10 tubes of 10 ml). Blood samples will be labeled with the patient's identification number as part of the protocol. They will be transported to the research laboratory in order to be picked up for monocyte extraction. The purification of blood monocytes will be done. In case of excess, the samples will be destroyed at the end of the study.
Study NCT05582746 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tri-City COVID Attitudes Study
Description: We propose a two-year study to rapidly assess (Aim 1), build and push (Aim 2), evaluate and disseminate (Aim 3) an mHealth intervention to boost COVID-19 testing and vaccine literacy, access, and uptake among women with CLSI in three cities
Study NCT06377852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 125mg
Description: Arm 1: Indicated dosing for palbociclib (125 mg orally daily on days 1-21 of 28-day cycle)
Study NCT06700096 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ANB-002
Description: Adeno-associated viral vector carrying the FIX gene single infusion
Study NCT05671510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gotistobart
Description: Gotistobart will be administrated through IV infusion over 60 minutes, once every 21 days in assigned dose.
Study NCT05671510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel will be administrated through IV infusion over 60 minutes, once every 21 days in 75mg/m2 dose.
Study NCT06377852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib 600mg
Description: Arm 1: Indicated dosing of ribociclib (600 mg orally daily on days 1-21 of 28-day cycle)
Study NCT06377852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Arm 2: Titrated dosing approach with the same schedule but starting at a lower dose of ribociclib (400 mg or 200 mg) and escalating the dose if well-tolerated in combination with provider/patient choice of endocrine therapy.
Study NCT06377852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Arm 2: Titrated dosing approach with the same schedule but starting at a lower dose of palbociclib (100 mg or 75 mg) and escalating the dose if well-tolerated in combination with provider/patient choice of endocrine therapy.
Study NCT05113966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib
Description: Single-use, sterile powder to be reconstituted and further diluted with 250 milliliters (mL) of normal saline (sodium chloride solution 0.9%) or dextrose 5% in water (D5W)
Study NCT05113966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy
Description: 10 milligram per kilogram (mg/kg) reconstituted to a concentration of 1.1 mg/mL to 3.4 mg/mL in normal saline
Study NCT04426968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepalatide 2.1mg
Description: 2.1 mg/day subcutaneously (s.c.) for 24 week
Study NCT04426968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepalatide 4.2mg
Description: 4.2mg/day subcutaneously (s.c.) for 24 week
Study NCT04426968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepalatide 6.3mg
Description: 6.3mg/day subcutaneously (s.c.) for 24 week
Study NCT04426968 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo 2.1mg
Description: 2.1 mg/day subcutaneously (s.c.) for 24 week
Study NCT04987996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GR-MD-02
Description: Patients will receive up to seventeen doses of GR-MD-02 intravenously over 85 Days.